Shenzhen iCarbonX Peptide Drug Technology

Shenzhen iCarbonX Peptide Drug Technology is a specialized subsidiary of iCarbonX, focusing on the discovery and development of novel peptide therapeutics using artificial intelligence and big data. The company leverages its parent organization's massive multi-omics data ecosystem to identify bioactive peptides and optimize their pharmacological properties for metabolic and inflammatory diseases. By integrating high-throughput screening with machine learning algorithms, the firm aims to accelerate the transition from digital health insights to tangible drug candidates. Its primary research focus includes next-generation metabolic regulators such as GLP-1 and glucagon receptor agonists.